Business Context and Reporting Period
This Form 8-K was filed by Spero Therapeutics, Inc. on October 3, 2019. The report discloses a material event regarding the Company's ongoing ADAPT-PO pivotal Phase 3 clinical trial for SPR994, an oral carbapenem product candidate.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements.
Material Changes
On October 3, 2019, an independent review committee evaluated interim pharmacokinetic plasma data from the ADAPT-PO trial. The committee recommended that the Company continue the trial without modification of the protocol-defined dose.
Guidance, Outlook, and Risks
Management commentary is limited to the positive outcome of the interim data review, which supports the continuation of the Phase 3 trial as planned. The filing does not provide specific financial guidance, updated risk factors, or details on contingencies beyond the clinical trial status.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed pharmacokinetic data.
- Confirm the current status of the ADAPT-PO Phase 3 trial enrollment and timeline.
- Review the Company's most recent 10-Q or 10-K for up-to-date financial liquidity and cash burn rates, as this 8-K contains no financial data.